Evaluating the Relationship of GDF-15 with Clinical Characteristics, Cardinal Features, and Survival in Multiple Myeloma
Growth differentiation factor 15 (GDF-15), a member of the transforming growth factor-β superfamily, participates in processes associated with myeloma development and its end-organ complications. It plays a significant role in both physiological and abnormal erythropoiesis and regulates iron homeost...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Mediators of Inflammation |
| Online Access: | http://dx.doi.org/10.1155/2020/5657864 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832551657883303936 |
|---|---|
| author | Małgorzata Banaszkiewicz Jolanta Małyszko Krzysztof Batko Ewa Koc-Żórawska Marcin Żórawski Paulina Dumnicka Artur Jurczyszyn Karolina Woziwodzka Joanna Tisończyk Marcin Krzanowski Jacek Małyszko Anna Waszczuk-Gajda Ryszard Drożdż Marek Kuźniewski Katarzyna Krzanowska |
| author_facet | Małgorzata Banaszkiewicz Jolanta Małyszko Krzysztof Batko Ewa Koc-Żórawska Marcin Żórawski Paulina Dumnicka Artur Jurczyszyn Karolina Woziwodzka Joanna Tisończyk Marcin Krzanowski Jacek Małyszko Anna Waszczuk-Gajda Ryszard Drożdż Marek Kuźniewski Katarzyna Krzanowska |
| author_sort | Małgorzata Banaszkiewicz |
| collection | DOAJ |
| description | Growth differentiation factor 15 (GDF-15), a member of the transforming growth factor-β superfamily, participates in processes associated with myeloma development and its end-organ complications. It plays a significant role in both physiological and abnormal erythropoiesis and regulates iron homeostasis through modulation of hepcidin. It is abnormally secreted in marrow stromal cells of patients with multiple myeloma (MM), which may reflect the tumor microenvironment. We analyzed the associations of serum GDF-15 with clinical characteristics of 73 MM patients (including asymptomatic MM) and the laboratory indices of renal function, anemia, and inflammation. Baseline serum GDF-15 was studied as the predictor of two-year survival. We defined five clinically relevant subgroups of patients (symptomatic MM only, patients with and without remission, patients on chemotherapy, and without treatment). Increased GDF-15 concentrations were associated with more advanced MM stage, anemia, renal impairment (lower glomerular filtration and higher markers of tubular injury), and inflammation. Most of the results were confirmed in the subgroup analysis. Serum cystatin C and urine neutrophil gelatinase-associated lipocalin were associated with GDF-15 independently of other variables. In the studied MM patients, GDF-15 did not significantly predict survival (p=0.06). Our results suggest that serum GDF-15 reflects myeloma burden and shares a relationship with several markers of prognostic significance, as well as major manifestations. |
| format | Article |
| id | doaj-art-2ec666558149477eba786a46ec52b46f |
| institution | Kabale University |
| issn | 0962-9351 1466-1861 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Mediators of Inflammation |
| spelling | doaj-art-2ec666558149477eba786a46ec52b46f2025-02-03T06:00:48ZengWileyMediators of Inflammation0962-93511466-18612020-01-01202010.1155/2020/56578645657864Evaluating the Relationship of GDF-15 with Clinical Characteristics, Cardinal Features, and Survival in Multiple MyelomaMałgorzata Banaszkiewicz0Jolanta Małyszko1Krzysztof Batko2Ewa Koc-Żórawska3Marcin Żórawski4Paulina Dumnicka5Artur Jurczyszyn6Karolina Woziwodzka7Joanna Tisończyk8Marcin Krzanowski9Jacek Małyszko10Anna Waszczuk-Gajda11Ryszard Drożdż12Marek Kuźniewski13Katarzyna Krzanowska14Chair and Department of Nephrology, Jagiellonian University Medical College, Kraków, PolandDepartment of Nephrology, Dialysis and Internal Medicine, Medical University of Warsaw, Warsaw, PolandChair and Department of Nephrology, Jagiellonian University Medical College, Kraków, PolandSecond Department of Nephrology and Hypertension with Dialysis Unit, Medical University of Bialystok, Bialystok, PolandDepartment of Clinical Medicine, Medical University of Bialystok, Bialystok, PolandDepartment of Medical Diagnostics, Jagiellonian University Medical College, Kraków, PolandChair and Department of Hematology, Jagiellonian University Medical College, Kraków, PolandChair and Department of Nephrology, Jagiellonian University Medical College, Kraków, PolandDepartment of Medical Diagnostics, Jagiellonian University Medical College, Kraków, PolandChair and Department of Nephrology, Jagiellonian University Medical College, Kraków, PolandFirst Department of Nephrology and Transplantology with Dialysis Unit, Medical University of Bialystok, Bialystok, PolandDepartment of Hematology, Oncology and Internal Diseases, Medical University of Warsaw, Warsaw, PolandDepartment of Medical Diagnostics, Jagiellonian University Medical College, Kraków, PolandChair and Department of Nephrology, Jagiellonian University Medical College, Kraków, PolandChair and Department of Nephrology, Jagiellonian University Medical College, Kraków, PolandGrowth differentiation factor 15 (GDF-15), a member of the transforming growth factor-β superfamily, participates in processes associated with myeloma development and its end-organ complications. It plays a significant role in both physiological and abnormal erythropoiesis and regulates iron homeostasis through modulation of hepcidin. It is abnormally secreted in marrow stromal cells of patients with multiple myeloma (MM), which may reflect the tumor microenvironment. We analyzed the associations of serum GDF-15 with clinical characteristics of 73 MM patients (including asymptomatic MM) and the laboratory indices of renal function, anemia, and inflammation. Baseline serum GDF-15 was studied as the predictor of two-year survival. We defined five clinically relevant subgroups of patients (symptomatic MM only, patients with and without remission, patients on chemotherapy, and without treatment). Increased GDF-15 concentrations were associated with more advanced MM stage, anemia, renal impairment (lower glomerular filtration and higher markers of tubular injury), and inflammation. Most of the results were confirmed in the subgroup analysis. Serum cystatin C and urine neutrophil gelatinase-associated lipocalin were associated with GDF-15 independently of other variables. In the studied MM patients, GDF-15 did not significantly predict survival (p=0.06). Our results suggest that serum GDF-15 reflects myeloma burden and shares a relationship with several markers of prognostic significance, as well as major manifestations.http://dx.doi.org/10.1155/2020/5657864 |
| spellingShingle | Małgorzata Banaszkiewicz Jolanta Małyszko Krzysztof Batko Ewa Koc-Żórawska Marcin Żórawski Paulina Dumnicka Artur Jurczyszyn Karolina Woziwodzka Joanna Tisończyk Marcin Krzanowski Jacek Małyszko Anna Waszczuk-Gajda Ryszard Drożdż Marek Kuźniewski Katarzyna Krzanowska Evaluating the Relationship of GDF-15 with Clinical Characteristics, Cardinal Features, and Survival in Multiple Myeloma Mediators of Inflammation |
| title | Evaluating the Relationship of GDF-15 with Clinical Characteristics, Cardinal Features, and Survival in Multiple Myeloma |
| title_full | Evaluating the Relationship of GDF-15 with Clinical Characteristics, Cardinal Features, and Survival in Multiple Myeloma |
| title_fullStr | Evaluating the Relationship of GDF-15 with Clinical Characteristics, Cardinal Features, and Survival in Multiple Myeloma |
| title_full_unstemmed | Evaluating the Relationship of GDF-15 with Clinical Characteristics, Cardinal Features, and Survival in Multiple Myeloma |
| title_short | Evaluating the Relationship of GDF-15 with Clinical Characteristics, Cardinal Features, and Survival in Multiple Myeloma |
| title_sort | evaluating the relationship of gdf 15 with clinical characteristics cardinal features and survival in multiple myeloma |
| url | http://dx.doi.org/10.1155/2020/5657864 |
| work_keys_str_mv | AT małgorzatabanaszkiewicz evaluatingtherelationshipofgdf15withclinicalcharacteristicscardinalfeaturesandsurvivalinmultiplemyeloma AT jolantamałyszko evaluatingtherelationshipofgdf15withclinicalcharacteristicscardinalfeaturesandsurvivalinmultiplemyeloma AT krzysztofbatko evaluatingtherelationshipofgdf15withclinicalcharacteristicscardinalfeaturesandsurvivalinmultiplemyeloma AT ewakoczorawska evaluatingtherelationshipofgdf15withclinicalcharacteristicscardinalfeaturesandsurvivalinmultiplemyeloma AT marcinzorawski evaluatingtherelationshipofgdf15withclinicalcharacteristicscardinalfeaturesandsurvivalinmultiplemyeloma AT paulinadumnicka evaluatingtherelationshipofgdf15withclinicalcharacteristicscardinalfeaturesandsurvivalinmultiplemyeloma AT arturjurczyszyn evaluatingtherelationshipofgdf15withclinicalcharacteristicscardinalfeaturesandsurvivalinmultiplemyeloma AT karolinawoziwodzka evaluatingtherelationshipofgdf15withclinicalcharacteristicscardinalfeaturesandsurvivalinmultiplemyeloma AT joannatisonczyk evaluatingtherelationshipofgdf15withclinicalcharacteristicscardinalfeaturesandsurvivalinmultiplemyeloma AT marcinkrzanowski evaluatingtherelationshipofgdf15withclinicalcharacteristicscardinalfeaturesandsurvivalinmultiplemyeloma AT jacekmałyszko evaluatingtherelationshipofgdf15withclinicalcharacteristicscardinalfeaturesandsurvivalinmultiplemyeloma AT annawaszczukgajda evaluatingtherelationshipofgdf15withclinicalcharacteristicscardinalfeaturesandsurvivalinmultiplemyeloma AT ryszarddrozdz evaluatingtherelationshipofgdf15withclinicalcharacteristicscardinalfeaturesandsurvivalinmultiplemyeloma AT marekkuzniewski evaluatingtherelationshipofgdf15withclinicalcharacteristicscardinalfeaturesandsurvivalinmultiplemyeloma AT katarzynakrzanowska evaluatingtherelationshipofgdf15withclinicalcharacteristicscardinalfeaturesandsurvivalinmultiplemyeloma |